


ZERO CANDIDA



It's Time Women's Issues Are Not **Left In The Dark**

The Problem

Candidiasis affects **75%** women worldwide at some point in their lifetime. Candidiasis a fungal infection causing irritation, discharge and intense itchiness of the vagina and the vulva.

Current Treatment

In many cases the existing medication is ineffective.

Therapeutic failures such as...

- Low drug bio-availability (short time of drug efficiency and high recurrence).
- Host susceptibilities (Immunosuppressive therapy, organ transplant, cancer, AIDS).
- Reduction in the intracellular level of drug (Biofilm presence, overuse and low response to drugs).

Our Solution

AI-driven smart tampon-like device combining...

- Therapy Light
- Gel based Clotrimazole

Used only up to one night and in 3 hours succeeded

99.999% elimination of the fungus without....

- Chemicals
- Side Effects
- Prescriptions

**Successful
Proof of
Concept
Twice in 2024**


Connecting you with your doctor through...

Wi-Fi and VoIP for personalized assessment, treatment and monitoring.



Market Outlook

Candidiasis recurrence affects hundreds of millions of women per year worldwide. The highest prevalence (9%) is seen in women between 24 and 35 years old.



Key Milestones

1. Founded

In 2022 by highly experienced team with proven track records in setting up and commercializing startups in the medical sector.

2. Product

Defined first prototype and completed production.

3. Development

Proof of Concept - almost 100% of the fungi eliminated in a bench test and successfully completed animal studies.

6. Infrastructure

Recruited world renowned key opinion leaders and scientists to its advisory board.

5. Intellectual Property

Patent application filed in USA, and patent granted in South Africa.

4. Market Validation

Gained initial market feedback with medical experts and signed pre-clinical agreements with hospitals in Europe and Israel.

7. Investment

Successfully completed raise - fully funded for scheduled clinical trials.

8. Market

Listing on TSX Venture at a proposed valuation of C\$40 M.

9. Product

Development of final product for human use in preparation for clinical trials.

On The Horizon....

Q1

Apply for OTC Listing and DTC Eligibility.

Q2

Complete Scheduled Clinical Trials.

Q3

Present Results to FDA for Review.

Q4

Apply for 510(k).

